Wahl AF - Search Results

1

Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.

Donaldson KL, Goolsby GL, Wahl AF. Donaldson KL, et al. Among authors: wahl af. Int J Cancer. 1994 Jun 15;57(6):847-55. doi: 10.1002/ijc.2910570614. Int J Cancer. 1994. PMID: 7911457

2

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF. Law CL, et al. Among authors: wahl af. Cancer Res. 2006 Feb 15;66(4):2328-37. doi: 10.1158/0008-5472.CAN-05-2883. Cancer Res. 2006. PMID: 16489038

3

In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF. Sanderson RJ, et al. Among authors: wahl af. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):843-52. Clin Cancer Res. 2005. PMID: 15701875

4

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.

Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF. Law CL, et al. Among authors: wahl af. Clin Cancer Res. 2004 Dec 1;10(23):7842-51. doi: 10.1158/1078-0432.CCR-04-1028. Clin Cancer Res. 2004. PMID: 15585616

5

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF. Francisco JA, et al. Among authors: wahl af. Blood. 2003 Aug 15;102(4):1458-65. doi: 10.1182/blood-2003-01-0039. Epub 2003 Apr 24. Blood. 2003. PMID: 12714494

6

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA. Wahl AF, et al. Cancer Res. 2002 Jul 1;62(13):3736-42. Cancer Res. 2002. PMID: 12097283

7

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.

Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF. Francisco JA, et al. Among authors: wahl af. Cancer Res. 2000 Jun 15;60(12):3225-31. Cancer Res. 2000. PMID: 10866315

8

Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.

Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Wahl AF, et al. Int J Cancer. 2001 Aug 15;93(4):590-600. doi: 10.1002/ijc.1364. Int J Cancer. 2001. PMID: 11477565

9

Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.

McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. McShea A, et al. Among authors: wahl af. Am J Pathol. 1997 Jun;150(6):1933-9. Am J Pathol. 1997. PMID: 9176387 Free PMC article.

10

Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest.

Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF. Horne MC, et al. Among authors: wahl af. J Biol Chem. 1997 May 9;272(19):12650-61. doi: 10.1074/jbc.272.19.12650. J Biol Chem. 1997. PMID: 9139721

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results